Internal Medicine, Hematology & Oncology · Tucson, AZ
NPI
1477817971
Since 2012
Specialty
Internal Medicine, Hematology & Oncology
Code 207RH0003X
Group practices
3
Medicare group memberships
Hospitals
3
Hospital affiliations
603 N Wilmot Rd Ste 151
Tucson, AZ, 85711
Phone (520) 420-2560
Groups this clinician bills Medicare through
Medicare paid, 2024
$2.3M
241,352 services
Medicare patients, 2024
681
Average age 75
Drug cost, 2024
$7.5M
1,605 prescriptions
Company payments, 2025
$13K
From 27 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Ahmed M Abdelaziz was code Q5110 (injection, filgrastim-aafi, biosimilar, (nivestym), 1 microgram), 27,360 times for 18 patients. In total Ahmed M Abdelaziz billed 241,352 services in 141 codes, and Medicare paid $2.3M.
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2025-05-22.
| Code |
|---|
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| Q5110 Injection, filgrastim-aafi, biosimilar, (nivestym), 1 microgram | Office | 27,360 | 18 | $0.22 | $6,057 |
| J9271 Injection, pembrolizumab, 1 mg | Office | 10,300 | 23 | $42.79 | $441K |
| J9267 Injection, paclitaxel, 1 mg | Office | 9,530 | 31 | $0.08 | $771 |
| J1453 Injection, fosaprepitant, 1 mg | Office | 8,250 | 37 | $0.11 | $920 |
| J0881 Injection, darbepoetin alfa, 1 microgram (non-esrd use) | Office | 6,320 | 13 | $2.35 | $15K |
| J9144 Injection, daratumumab, 10 mg and hyaluronidase-fihj | Office | 6,120 | 11 | $38.17 | $234K |
| J0185 Injection, aprepitant, 1 mg | Office | 5,200 | 20 | $1.34 | $6,955 |
| J1100 Injection, dexamethasone sodium phosphate, 1 mg | Office | 2,053 | 93 | $0.09 | $183 |
| J1437 Injection, ferric derisomaltose, 10 mg | Office | 2,000 | 17 | $15.94 | $32K |
| J1626 Injection, granisetron hydrochloride, 100 mcg | Office | 1,530 | 54 | $0.25 | $384 |
| J0897 Injection, denosumab, 1 mg | Office | 1,440 | 14 | $20.26 | $29K |
| J2469 Injection, palonosetron hcl, 25 mcg | Office | 1,300 | 72 | $0.73 | $946 |
| 96375 Injection Administration | Office | 666 | 130 | $11.64 | $7,752 |
| J0640 Injection, leucovorin calcium, per 50 mg | Office | 599 | 12 | $3.65 | $2,185 |
| J9190 Injection, fluorouracil, 500 mg | Office | 424 | 16 | $2.36 | $1,002 |
By year: 2022 $2.4M for 216,137 services; 2023 $2.4M for 221,088 services; 2024 $2.3M for 241,352 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 36415 Venipuncture Blood Collection | 12 | 12 | $8.65 | $104 |
Medicare prescription drug claims, 2024
In 2024, the drug Ahmed M Abdelaziz prescribed most often to Medicare patients was Eliquis (Apixaban), with 109 prescriptions and refills. In total Ahmed M Abdelaziz wrote 1,605 Medicare prescriptions that cost $7.5M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Eliquis Apixaban | 109 | 194 | 27 | $117K |
| Acyclovir Generic | 104 | 179 | 29 | $1,181 |
| Prednisone Generic | 81 | 104 | 29 | $393 |
| Xarelto Rivaroxaban | 72 | 107 | 13 | $59K |
| Ondansetron Hcl Generic | 71 | 78 | 46 | $1,136 |
| Prochlorperazine Maleate Generic | 67 | 67 | 39 | $1,326 |
| Brukinsa Zanubrutinib | 66 | 67 | Under 11 | $704K |
| Dexamethasone Generic | 57 | 63 | 22 | $839 |
| Calquence Acalabrutinib Maleate | 44 | 44 | Under 11 | $674K |
| Olanzapine Generic | 41 | 41 | 26 | $323 |
| Mekinist Trametinib Dimethyl Sulfoxide | 32 | 32 | Under 11 | $526K |
| Tafinlar Dabrafenib Mesylate | 32 | 32 | Under 11 | $448K |
| Jakafi Ruxolitinib Phosphate | 31 | 35 | Under 11 | $580K |
| Letrozole Generic | 30 | 89 | 11 | $859 |
| Levothyroxine Sodium Generic | 30 | 71 | Under 11 | $321 |
Brand drugs: 630 claims; generic drugs: 975 claims; opioid claims: 66.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Ahmed M Abdelaziz $13K ($13K in general payments such as food, travel and fees) from 27 companies. The largest payer was Amgen Inc. with $11K.
| Company | Payments | Amount |
|---|---|---|
| Amgen Inc. AMGN | 8 | $11K |
| AstraZeneca Pharmaceuticals LP AZN | 10 | $242 |
| Novartis Pharmaceuticals Corporation NVS | 9 | $223 |
| Pfizer Inc. PFE | 10 | $155 |
| Celgene Corporation BMY | 8 | $149 |
| Sumitomo Pharma America, Inc. 4506.T | 6 | $147 |
| GlaxoSmithKline, LLC. GSK | 6 | $122 |
| Janssen Biotech, Inc. JNJ | 1 | $99 |
| Daiichi Sankyo Inc. 4568.T | 4 | $88.03 |
| Abbvie Inc. ABBV | 4 | $87.6 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.